Biotts SA

What Biotts SA does

Biotts SA is a privately held Polish biotech company founded in 2018 and headquartered in Bielany Wrocławskie (with R&D operations in Wrocław) that develops proprietary transdermal drug delivery technology branded as MTC-Y (Multifunctional Transdermal Carrier Y). MTC-Y is a semi-solid emulsion carrier system that enables skin permeation of both lipophilic and hydrophilic molecules, including peptides and proteins up to 6,000 Daltons, without breaking the skin surface, an order-of-magnitude expansion over the <500 Da small-molecule limit of conventional transdermal systems. The company serves the global pharmaceutical industry and operates a dual-entity structure (Biotts S.A. in Poland and Biotts INC. in Boston, Massachusetts).

Biotts pursues three interlocking revenue tracks. First, it advances its own proprietary drug candidates on the MTC-Y platform: MTC-D (transdermal dapagliflozin) has completed a Phase 1 clinical trial, MTC-INS (transdermal insulin) is in preclinical development under a strategic partnership with BIOTON S.A. targeting FDA/EMA submissions by 2027, MTC-A4 (a 4%/4% tetracaine-lidocaine topical anesthetic) received US patent protection in January 2025, and transdermal semaglutide plus a wound-healing preparation for diabetic foot ulcers are in earlier development. Second, the company licenses the MTC-Y platform and enters technical co-development collaborations with pharmaceutical partners (SERVIER is a named collaborator). Third, Biotts sells GMP-certified contract R&D and laboratory services covering formulation development, analytical and stability testing, Franz cell diffusion studies, and regulatory documentation to pharmaceutical, biotechnology, cosmetics, and dietary supplement clients.

The go-to-motion is enterprise field sales layered onto heavy conference activity (CPHI, BIO-Europe, ATTD, PODD, LSX, RESI, BioJapan, SusHi Tech Tokyo), supported by peer-reviewed publications in Pharmaceutics, Frontiers in Pharmacology, and Nature Scientific Reports. The company is privately held, venture- and grant-funded (cumulative EU grants of approximately 17.7 million PLN across multiple projects, a $1.5 million Montis Capital round in 2020, Google for Startups participation in 2021, and EIC Accelerator funding in 2026), and holds granted US patents on both the MTC-Y carrier (November 2025) and the MTC-A4 anesthetic (January 2025), with additional protection in Poland and Canada.

Name

Biotts SA

Legal name

Biotts INC.

Website

https://biotts.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Biotts SA is a Polish biotech company developing the proprietary MTC-Y transdermal carrier technology that enables needle-free delivery of peptides and proteins up to 6,000 Da. It advances proprietary drug candidates in diabetes and offers GMP-certified R&D services to pharmaceutical partners.

Ownership category

akta.pro rank

Headquarters

HQ city

Bielany Wroclawskie

HQ country

Poland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Proprietary Drug Product Development: Biotts develops its own transdermal drug products using MTC-Y technology, advancing candidates through clinical development with the goal of commercializing novel transdermal therapies.
2. Contract R&D and Laboratory Services: GMP-certified research and development services offered to pharmaceutical, biotechnology, cosmetics, and dietary supplements companies. Services include formulation development, analytical testing, stability studies, and regulatory support.
3. Technology Licensing and Development Collaborations: Making MTC-Y technology available to pharmaceutical industry through technical development collaborations, partnership agreements, and licensing arrangements.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Biotts SA develops and commercializes proprietary transdermal drug delivery systems based on its patented MTC-Y™ (Multifunctional Transdermal Carrier Y) semi-solid carrier technology, which enables needle-free delivery of large-molecule therapeutics (up to 6,000 Da) including peptides and proteins. The company develops its own drug candidates (transdermal insulin, dapagliflozin, semaglutide, topical anesthetics) and also offers GMP-certified contract R&D and laboratory services to pharmaceutical, biotech, cosmetics, and dietary supplement companies.

Product overview

Biotts SA is a biotech company specializing in transdermal drug delivery with its proprietary MTC-Y™ (Multifunctional Transdermal Carrier Y) technology as the core platform. The technology enables delivery of both lipophilic and hydrophilic molecules including large peptides and proteins (up to 6,000 Da) through the skin without breaking the skin surface. The product portfolio includes specific drug formulations developed using the MTC-Y platform: MTC-INS (transdermal insulin), MTC-D (transdermal dapagliflozin), MTC-A4 (topical anesthetic), and transdermal semaglutide. Beyond proprietary drug development, Biotts offers GMP-certified contract R&D and laboratory services for pharmaceutical, biotechnology, cosmetics, and dietary supplements companies, providing end-to-end support from formulation through analytical validation.

Differentiator

Problem solved

Functional benefit

Products and services

• MTC-Y™ Multifunctional Transdermal Carrier MTC-Y™ is Biotts' proprietary semi-solid emulsion carrier technology that enables transdermal delivery of both lipophilic and hydrophilic molecules up to 6,000 Da, including peptides and proteins, without breaking the skin surface. It serves as the foundational platform for Biotts' drug development pipeline and is licensed to pharmaceutical partners.
• MTC-INS Transdermal Insulin Patch MTC-INS is a transdermal insulin delivery system using MTC-Y technology that demonstrated 55.1% bioavailability in preclinical studies, sustains therapeutic concentrations for up to 5 days in rat models, and achieves 70% of subcutaneous bioavailability in Göttingen Minipig studies. It is being developed to replace daily insulin injections for diabetes patients in partnership with BIOTON S.A.
• MTC-D Transdermal Dapagliflozin System MTC-D is a transdermal SGLT2 inhibitor system (TTS MTC-D) that successfully completed Phase 1 clinical study, demonstrating safety and effective drug delivery through the skin into the bloodstream. It targets diabetes treatment via needle-free administration.
• MTC-A4 Topical Anesthetic MTC-A4 is a novel topical anesthetic formulation combining 4% tetracaine and 4% lidocaine using MTC-Y technology, offering improved stability, reduced side effects, and more stable blood concentrations over 24 hours compared to the 7% Pliaglis formulation.
• Transdermal Semaglutide Transdermal formulation of GLP-1 receptor agonist semaglutide using MTC-Y technology, in preclinical/development stage with planned clinical trials. It targets needle-free delivery of GLP-1 therapies for diabetes and obesity.
• Transdermal Wound Healing Products Transdermal preparations for treatment of difficult-to-heal wounds and diabetic foot ulcers using hydrophilic natural substances, developed with EU funding under the Bridge Alfa program.
• GMP-Certified R&D Services Comprehensive GMP-compliant research and development services for pharmaceutical, biotechnology, cosmetics, and dietary supplements companies. Services include formulation development, analytical CMC support, stability testing, and CDMO services.
• Pharmaceutical R&D Services Early drug development services including ADME/DMPK, pharmacology, toxicology, formulation and drug form development, stability and release testing, analytical services, process development and scale-up, and regulatory documentation support for pharmaceutical companies.
• Cosmetic R&D Services Custom cosmetic formula development, Franz cell diffusion studies for penetration testing, HPLC/spectrometry analysis, stability testing, and EU Cosmetics Regulation compliance support for cosmetics and personal care companies.
• Dietary Supplements R&D Services Formulation development, composition analysis (vitamins, minerals, plant extracts), functional testing, product safety testing, and regulatory documentation for GIS compliance for dietary supplements companies.

Quantifiable outcome

• 55% bioavailability for transdermal insulin delivery demonstrated in preclinical studies
• +5 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• BIOTON S.A.coreStrategic or Co-development Partner · 7 December 2023Strategic collaboration with BIOTON S.A. (one of the world's top eight commercial manufacturers of recombinant human insulin) for pioneering transdermal insulin delivery. The partnership combines Bioton's insulin expertise with Biotts' MTC-Y technology to develop needle-free insulin administration. Goal is to bring transdermal insulin to market by 2027, with clinical trials planned for early 2025 and regulatory submissions to FDA and EMA in parallel.
• SERVIERcoreStrategic or Co-development Partner · 24 January 2022SERVIER started cooperation with Biotts to work on technology that improves patient quality of life. Collaboration focused on developing transdermal delivery solutions leveraging Biotts' MTC-Y technology.
• LPP Equipment Sp. z o.o.minorOthersSelected as supplier for automated transdermal diffusion testing system with Franz chambers for EU-funded project on transdermal preparations for difficult-to-heal wounds and local anesthetics.
• University of OpoleminorStrategic or Co-development PartnerResearch partner for Lower Silesian Innovation Voucher project conducting molecular structure analysis of transdermal carrier using hydrophilic natural substances for wound healing applications.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Corium Inc. Corium is a US transdermal drug delivery specialist developing and commercializing patch-based products using proprietary permeation technologies. Directly comparable to Biotts in its focus on next-generation transdermal systems that expand beyond small-molecule patches, serving pharma partners with both proprietary and partnered products.
• Kindeva Drug Delivery: Kindeva (formerly 3M Drug Delivery Systems) is a global contract developer and manufacturer specializing in transdermal patches, inhalation, and microneedle systems. Highly comparable to Biotts on the contract R&D/CDMO dimension and on transdermal technology innovation, serving large pharma partners.
• Noven Pharmaceuticals: Noven, a subsidiary of Hisamitsu Pharmaceutical, develops and manufactures transdermal drug delivery patches for central nervous system and hormone therapies. Comparable as a focused transdermal patch innovator with proprietary formulation IP, overlapping customer base in pharma, and shared emphasis on expanding transdermal indications.
• Teikoku Pharma: Teikoku Pharma is a Japanese specialty pharma focused on transdermal patches for pain, Parkinson's, and hormone replacement. Comparable in its emphasis on proprietary transdermal technology, sustained-release profiles, and partnering with global pharma for out-licensing of patch IP.

Emerging players

• Zosano Pharma: Zosano develops microneedle transdermal delivery systems for large molecules and peptides. Comparable as an emerging needle-free delivery technology developer targeting the same kind of biologics (peptides, proteins) that Biotts' MTC-Y aims to deliver — a partial-overlap peer on the large-molecule transdermal frontier.
• Dermavant Sciences: Dermavant is a Roivant-backed dermatology company developing topical therapeutics with novel formulations. Comparable as an emerging player applying proprietary delivery technology to expand what topical/transdermal products can achieve — meaningful overlap on formulation innovation in skin-applied drug delivery.
• Vaxess Technologies: Vaxess develops a needle-free transdermal patch platform (using microneedles/hyaluronic tips) initially for vaccines and large molecules. Comparable as a small, venture-backed transdermal technology developer aiming to deliver biologics through the skin — competing for the same needle-free biologic delivery frontier.

Broad incumbents

• Hisamitsu Pharmaceutical: Hisamitsu is the global leader in OTC and prescription transdermal patches (Salonpas, etc.) and parent of Noven. Comparable as a broad incumbent in transdermal delivery — overlapping technology, customer base, and route of administration — but with vastly greater scale, manufacturing footprint, and commercial reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biotts

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biotts SA